Blueprint to Combat Neonatal Sepsis and AMR in Bangladesh

Sepsis, a severe bloodstream infection, has evolved into a major public health threat. When coupled with Antimicrobial Resistance (AMR), it directly imperils the future of newborns in Bangladesh. The first 28 days of life constitute an exceptionally fragile window. A bacterial infection invading the bloodstream during this period is clinically defined as neonatal sepsis. This condition stands as a major global health crisis. Annually, over 10 million newborns develop this infection worldwide, resulting in approximately 200,000 to 250,000 deaths.

The situation in Bangladesh is uniquely alarming. Nearly 18,000 newborns die from infections here each year. While neonatal sepsis is multifactorial—driven by complex clinical, environmental, and socioeconomic vulnerabilities—AMR significantly complicates treatment and causes a high number of fatalities. Recognising the symptoms of sepsis remains inherently challenging. An infected infant typically feeds less than usual, exhibits severe lethargy, experiences rapid breathing, and suffers from an abnormally high or low body temperature. Because these clinical presentations mimic common, benign illnesses, diagnostic delays are frequent.

Timing is absolutely critical in neonatal care. The administration of effective antibiotics must occur as early as possible. Any delay allows the infection to become rapidly fatal. Even when infants survive, they often sustain long-term physical and neurological complications that permanently hinder normal childhood development. While AMR severely limits the effectiveness of standard treatments and is now classified as a silent pandemic, resolving this crisis requires a balanced approach that equally addresses diagnostic delays, weak Infection Prevention and Control (IPC) measures, and inequitable access to timely treatment. If current trajectories persist, AMR could claim 10 million lives annually worldwide by 2050.

Dhaka context through an epidemiological lens

A crucial scientific study was conducted in Bangladesh to determine the incidence of severe infections among infants under 60 days of age. Titled "Severe Infection Incidence Among Young Infants in Dhaka, Bangladesh: An Observational Cohort Study," the research monitored 1,939 healthy newborns in Dhaka. The empirical data revealed striking insights. Based on the primary case definition—requiring a direct clinical diagnosis by a physician and a minimum of five days of parenteral antibiotic treatment—the severe infection rate stood at 1.2 per 1,000 infant-days.

Read More

The Reign of Superbugs in Bangladesh’s ICUs and NICUs: A Silent Pandemic

In contrast, the rate was 0.84 based on the World Health Organization's (WHO) definition of Possible Serious Bacterial Infection (pSBI). It fell to 0.026 for infections confirmed strictly through blood culture. The investigators issued a stern warning against relying solely on physical signs and symptoms for diagnosis. Such a localised diagnostic approach risks missing a substantial proportion of childhood sepsis cases. Direct clinical evaluation and timely physician consultation remain indispensable.

Grim reality in neonatal intensive care units

Separate clinical data highlighted an exceptionally high prevalence of bloodstream infections among hospitalised newborns. A study conducted by the Institute of Child and Mother Health (ICMH) in Dhaka analysed the ground reality within a major tertiary care hospital. The findings revealed that 69.6% of all newborns admitted to the neonatal intensive care unit (NICU) had active sepsis. Crucially, 60.9% of these cases were classified as early-onset infections, occurring immediately after birth. The researchers identified several primary risk factors driving these sepsis rates. Low birth weight, specifically between 1.5 and 2.4 kilograms, drastically increases vulnerability. A lack of maternal education emerged as another major socioeconomic risk factor. 

Expert observations and epidemiological surveillance

Addressing this crisis requires the immediate application of insights from frontline experts. Dr Mohammad Shahidul Islam, an associate scientist and senior research investigator at the Child Health Research Foundation (CHRF), said that AMR has escalated into a major public health crisis in Bangladesh. Their extensive laboratory surveillance shows that the majority of bacteria isolated from neonatal sepsis cases now exhibit resistance to one or more conventional antibiotics.

Recent clinical trials paint an even more distressing picture. A large number of first-line drugs officially approved by the World Health Organization have lost their clinical efficacy in the country. This creates an immense challenge for physicians in selecting appropriate treatment regimens. 

Clinical realities in tertiary paediatric care

Providing a view from the clinical frontline, Mohammad Monir Hossain, professor of neonatal medicine, NICU, and critical care paediatrics at the Bangladesh Institute of Child Health (BICH) and Dhaka Shishu Hospital, observed that common neonatal infections are becoming increasingly complex. This is because conventional antibiotics are failing to work effectively. Infants frequently arrive at tertiary centres with resistance to multiple drug classes. This leaves clinicians with very limited alternative therapeutic options. Shockingly, broad-spectrum drugs utilised as standard first-line therapies in developed nations are effective in only 25% of cases in Bangladesh. To address this challenge, hospitals must strengthen their Infection Prevention and Control (IPC) measures.

Strategic roadmap to sustainable solutions

Childhood immunisation infrastructure must be substantially strengthened. Expanding vaccination programmes prevents a wide array of infectious diseases at an early stage, structurally reducing the clinical demand for antibiotics. Simultaneously, stringent regulatory enforcement must be applied to hospital bio-waste management and the non-therapeutic use of antibiotics within the commercial poultry and livestock sectors. Crucially, while strengthening antimicrobial stewardship is non-negotiable, the national strategic roadmap must explicitly secure timely access to quality-assured and appropriate antibiotics to improve neonatal sepsis survival rates. 

If the nation fails to confront this silent pandemic immediately, minor, common infections will become fatal for future generations. In Bangladesh, reducing neonatal mortality and achieving the Sustainable Development Goals depend entirely on preventing sepsis and controlling AMR. A unified approach across the health sector, industry, and policymaking is the only way to safeguard future generations.

The write-up is a part of Without Borders Media Fellowship by MSF-GARDP Grant on Antimicrobial Resistance, which encourages independent, impartial, and neutral reporting on health and humanitarian crises. 

The writer is an MPhil researcher at the University of Dhaka. He can be reached at [email protected]